Deinove gets FDA fast-tracked C diff candidate through Biovertis acquisition

13 April 2018
mergers-acquisitions-big

Shares in Paris-based biotech Deinove (Euronext: ALDEI) are trading almost a tenth higher for the day on news that it has bought the Austrian firm Biovertis, through a ‘contribution in kind’ transaction valued at around 900,000 euros ($1.1 million).

.

Biovertis owns German company Morphochem, whose antibiotic candidate MCB3837 is about to enter Phase II testing as a treatment for severe clostridium difficile gastrointestinal infections (CDI).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology